EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Effects of DPP ‐4 inhibitors, GLP ‐1 receptor agonists, SGLT ‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach

Andreas Brønden, Mikkel Bring Christensen, Dorte Glintborg, Ole Snorgaard, Allan Kofoed-Enevoldsen, Gitte Krogh Madsen, Katja Toft, Jette Kolding Kristensen, Kurt Højlund, Troels Krarup Hansen, Esben Søndergaard, Katrine Bagge Hansen iD

Diabetic Medicine · 2023

DOI: 10.1111/dme.15157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetic Medicine, 2023. Verfasst von Andreas Brønden und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Heart Failure. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of our meta‐analyses was to compare the effects of glucose‐lowering drugs on mortality, cardiovascular and renal endpoints for a range of type 2 diabetes (T2D) subgroups defined by their specific cardiovascular risk profile.

Methods

Meta‐analyses comparing drugs within the classes of GLP‐1RAs and SGLT‐2 inhibitors were performed and compared to sulphonylureas and DPP‐4 inhibitors with available cardiovascular outcome trials. The comparison between the different classes of glucose‐lowering drugs included analyses of T2D populations with low risk and high risk for cardiovascular disease including populations with established cardiovascular disease and/or kidney disease. Outcomes included mortality, major cardiovascular adverse events (MACE), hospitalisation for heart failure (HHF) and a composite renal endpoint as applied in the underlying clinical trials.

Results

SGLT‐2 inhibitors and GLP‐1RAs showed beneficial effects on mortality and MACE compared to the classes of DPP‐4 inhibitors and sulphonylureas. SGLT‐2 inhibitors were shown to be the most effective treatment in terms of HHF and kidney disease. Metformin was used as background therapy for the vast majority of participants in all included studies. Overall, the absolute effects of SGLT‐2 inhibitors and GLP‐1RAs on these important outcomes were evident for patients with established or at high risk for cardiovascular disease but limited for the low‐risk subgroup.

Conclusions

The findings from our analyses substantiate the relevance of treatment with SGLT‐2 inhibitors or GLP‐1RAs as an add‐on to metformin in patients with T2D and a high risk for cardiovascular disease, and furthermore, support the recommendation for SGLT‐2 inhibitor treatment in patients with T2D and heart failure or established kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHeart FailureMetforminSodium-Glucose Transporter 2 InhibitorsHumansGlucoseHypoglycemic AgentsSulfonylurea CompoundsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

DPP-IV inhibitorGLP-1 receptor agonistSGLT2 inhibitorcardiovascular outcomeseffectivenessmortalitynetwork meta-analysisrenal outcomessulphonylureas

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucoseHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Danish Medicines Council, Copenhagen, Denmark.
  • Department of Endocrinology, Amager and Hvidovre Hospital, Copenhagen, Denmark.
  • Steno Diabetes Center Zealand, Nykøbing Falster Hospital, Nykøbing Falster, Denmark.
  • Roskilde Medical Center, Roskilde, Denmark.
  • Center for General Practice, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Katrine Bagge Hansen

Zitieren

APA

Brønden, A., Christensen, M. B., Glintborg, D., Snorgaard, O., Kofoed-Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., Søndergaard, E., & Hansen, K. B. (2023). Effects of DPP ‐4 inhibitors, GLP ‐1 receptor agonists, SGLT ‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach. Diabetic Medicine. https://doi.org/10.1111/dme.15157

Vancouver

Brønden A, Christensen MB, Glintborg D, Snorgaard O, Kofoed-Enevoldsen A, Madsen GK, et al. Effects of DPP ‐4 inhibitors, GLP ‐1 receptor agonists, SGLT ‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach. Diabetic Medicine. 2023. doi:10.1111/dme.15157

BibTeX
@article{Brnden2023,
  author = {Brønden, Andreas and Christensen, Mikkel Bring and Glintborg, Dorte and Snorgaard, Ole and Kofoed-Enevoldsen, Allan and Madsen, Gitte Krogh and Toft, Katja and Kristensen, Jette Kolding and Højlund, Kurt and Hansen, Troels Krarup and Søndergaard, Esben and Hansen, Katrine Bagge},
  title = {Effects of DPP ‐4 inhibitors, GLP ‐1 receptor agonists, SGLT ‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach},
  journal = {Diabetic Medicine},
  year = {2023},
  doi = {10.1111/dme.15157}
}
Kostenlos starten →